Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06496217 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
A Phase 1 study of Renal Impairment, sponsored by MBX Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT06496217 is a Phase 1 study of Renal Impairment that has completed, run by MBX Biosciences. The registered enrollment target is 25 participants, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (26% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06496217, a Phase 1 study of Renal Impairment, has completed, sponsored by MBX Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function
Conditions Studied
Interventions
- DRUG MBX 2109
Study Locations (3)
Florida
- MBX Biosciences Investigational Site - Miami
- MBX Bioscience Investigational Site - Tampa
Minnesota
- MBX Biosciences Investigational Site - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-06-13 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06496217
The ClinicalTrials.gov registry entry for NCT06496217 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (26% lower). The listed sponsor is MBX Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which MBX 2109 is the first listed.
NCT06496217 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06496217 about?
NCT06496217 is a clinical study titled "Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function". Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function
What is the current status of trial NCT06496217?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2024-06-13. Estimated completion is 2025-09-04.
What conditions does trial NCT06496217 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT06496217?
The interventions under investigation include: MBX 2109 (DRUG).
Who is sponsoring clinical trial NCT06496217?
This trial is sponsored by MBX Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06496217 being conducted?
This trial has 3 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.